The Parker Institute sponsors several immunotherapeutic clinical trials. These are the PICI trials currently open for accrual at MSKCC.
An Exploratory Study of Nivolumab with or without Ipilimumab Immunotherapy According to Tumor CD8 Level in Patients with Advanced Cancer
A Phase II Study of Immunotherapy: Ipilimumab Alone or with Nivolumab in Patients Whose Melanoma Continues to Grow Despite Nivolumab or Pembrolizumab
A Phase IB/II Study of APX005M Immunotherapy plus Gemcitabine and nab-Paclitaxel, with or without Nivolumab, in Patients with Previously Untreated Metastatic Pancreatic Cancer